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High Rates of
Tuberculosis in
End-Stage Renal
Failure: The Impact
of International
Migration
David A.J. Moore, Liz Lightstone, Babak Javid, and 
Jon S. Friedland
We studied a cohort of patients requiring renal dialysis who had
migrated to the United Kingdom from tuberculosis (TB)-
endemic countries and found extremely high rates of TB (1,187
cases per 100,000 per year), partly associated with end-stage
diabetic renal disease. We recommend enhanced vigilance and
screening of such patients, both to reduce illness and death and
to prevent nosocomial spread of TB among susceptible per-
sons. 
mmigrants, asylum seekers, and refugees from war and
oppression often originate in countries where tuberculosis
(TB) is endemic and relocate to more affluent countries, where
the incidence of TB is low. A proportion of such persons will
have or develop renal failure requiring renal replacement ther-
apy (hemodialysis or continuous ambulatory peritoneal dialy-
sis [CAPD]). Chronic renal failure impairs immune function
and is associated with an increased incidence of TB. Among
patients with chronic renal failure requiring renal replacement
therapy, rates of TB 10- to 25-fold greater than those in the
general population have been reported from the United States,
Canada, Europe, and Japan, equating to incidence rates of
approximately 250 cases per 100,000 per year (1-3). In areas of
TB endemicity, the relative risk attributable to chronic renal
failure requiring dialysis appears to be similar (4), although as
the background rate in these settings is so much greater the
absolute rate will be considerably higher. The impact of inter-
national migration and the increase in asylum seekers and refu-
gees on the incidence of TB in renal dialysis patients has not
been previously explored.
The Study 
We investigated the incidence of TB in patients referred for
dialysis over a 5-year period (April 1, 1994, to March 31,
1999) to the Hammersmith Hospital, situated in an area of
London that is home to many immigrants, refugees, and asy-
lum seekers. A mean of 156 patients underwent dialysis in the
Hammersmith Dialysis Unit each year of the study; a mean of
45 patients were new to the program each year. Patients in the
renal replacement therapy cohort database who had been diag-
nosed with and treated for TB were identified by manual
searching of hospital microbiology and histopathology data-
bases and the handwritten logbook in which all local reports to
the U.K. Communicable Disease Surveillance Centre are
recorded. Duration of follow-up under the care of the renal unit
(within the specified 5-year study period) was calculated for
each patient. The length of time that patients had been resident
in the United Kingdom was not available. Eleven TB cases
(two fatal; the remainder making a complete recovery follow-
ing treatment) were identified from 431 dialysis patients,
including 191 who received peritoneal dialysis (CAPD). The
incidence of TB was 1,187 cases per 100,000 renal patients per
year. Case notes for all but one patient diagnosed with TB
were available for review. 
Patients had been on dialysis for 24.5 ±8.5 months (± stan-
dard error of the mean). During the study period, the total dial-
ysis population at the Hammersmith Hospital comprised 41%
Caucasians, 40% Asians, 18% black Caribbeans, and 1% from
other parts of the world, including six from the Indian subcon-
tinent, three from sub-Saharan Africa, and one from the
Republic of Ireland. All the TB patients were born overseas.
During the period of study, patients were not consistently
screened for TB at time of entry into the United Kingdom.
Specific screening of renal failure patients was also not rou-
tine, and no patient in our group received any form of chemo-
prophylaxis. In general, purified protein derivative (PPD)
testing is not routine in the United Kingdom, where most of the
population has had BCG vaccination or exposure to infection.
PPD responses are less useful in the renal failure population,
who tend to be anergic. Two of our patients did have PPD tests
during diagnostic workup; results were negative. 
Patients were treated with standard quadruple therapy of
isoniazid, rifampicin, pyrazinamide, and ethambutol for 2
months; isoniazid and rifampicin treatment continued for 4 to
10 months thereafter. Once a fully sensitive pathogen had been
cultured, ethambutol was discontinued. Nine of the 11 TB
patients had fully drug-sensitive organisms. For the other two,
diagnosis was histologic only, but complete cure followed
standard therapy. However, there were some delays in diagno-
sis, and one patient died before the diagnosis was confirmed by
culture of Mycobacterium tuberculosis from peritoneal fluid.
Despite this, infection did not develop in any staff or other
patient contacts found by contact tracing. In four (40%) of the
TB patients, the underlying cause of renal failure was diabetes
mellitus, although only 19% of the total dialysis population
had diabetes (13% of Caucasians, 24% Asians, and 19% Afro-
Caribbeans). Other causes of renal failure included hyperten-
sion, chronic pyelonephritis, immunoglobulin A nephropathy,
and HIV nephropathy (only one of six patients tested was HIV
seropositive). When first seen, six patients had pulmonary or
pleural TB, including one patient with empyema. Four patients
had peritoneal, two lymph node, and one hepatic TB. Of the
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six patients with pulmonary TB, one also had peritoneal TB
and one had concomitant lymph-node infection. No evidence
suggested an outbreak of TB, and no clustering of cases
occurred (three cases occurred in 1994, two in 1995, one in
1996, three in 1997, and two in 1998).
Conclusions 
Our study showed that the incidence of TB in patients
requiring dialysis is extremely high and 100-fold greater than
the incidence of TB in the general population of England and
Wales, which was 12 per 100,000 in 1998 (5). These figures
are probably an underestimate of the extent of TB in renal dis-
ease since ascertainment was based on definitive microbiologic
or histologic confirmation of diagnosis and legally required
reports. We cannot exclude the possibility that occasional
patients were treated on the basis of clinical suspicion and not
reported. Nor did we evaluate TB cases in dialysis-independent
patients with renal failure.
Part of the explanation for our findings is that patients
came from countries where TB is endemic. However, TB inci-
dence rates in England and Wales from 1988 to 1998 were, at
the most, 210 and 132 per 100,000 population among black
African patients and patients from the Indian subcontinent,
respectively (5), figures which are substantially less than in our
renal replacement therapy patients. Two other factors likely to
contribute to the high rates of TB are renal failure (1-3) and the
high prevalence of diabetes mellitus in patients from the Indian
subcontinent, a group in whom we have noted a high incidence
of end-stage renal disease (6). Diabetes mellitus appears to be
associated with TB in patients with renal failure (7). Although
most disease was pulmonary, peritoneal TB in CAPD patients
is relatively common, and the diagnosis should always be con-
sidered in patients with persistent conventional culture-nega-
tive peritonitis. 
Two of our patients died, which may reflect the fact that
the clinical symptoms of TB can be difficult to distinguish
from those of uremia, causing delay in diagnosis, although
dialysis-dependent renal failure has been shown to be a potent
contributor to death (8). HIV infection is an infrequent cause of
chronic renal failure among patients at the Hammersmith Hos-
pital and was not a major influence on TB reactivation in this
patient group. However, our data suggest that renal failure
requiring renal replacement therapy is as potent a risk factor
for reactivation of TB as any (including HIV infection) previ-
ously described.
There are two important messages from this study, which
showed that renal failure in immigrants is associated with
extremely high rates of TB in the context of migration from
disease-endemic areas and a high incidence of diabetes melli-
tus. First, it is critical that screening for latent TB infection in
patients with renal failure occur at a very early stage in people
who come from areas of the world where TB is endemic, a rec-
ommendation in line with those of the American Thoracic
Society, Centers for Disease Control and Prevention, and the
Council of the Infectious Diseases Society of America (9).
Treatment for latent TB infection should be routinely consid-
ered in such patients. Although the sensitivity of TB skin test-
ing is substantially reduced in the setting of chronic renal
failure with rates of anergy in excess of 30% (10), this should
not preclude its use as a screening tool because specificity is
unaltered. Second, since chronic renal failure necessitates fre-
quent attendance at medical facilities, the potential for nosoco-
mial spread among susceptible persons is considerable.
Enhanced vigilance is necessary to ensure early diagnosis of
infectious cases and prompt institution of appropriate therapy. 
Dr. Moore is a fellow in Infectious Diseases, who has a special
interest in tuberculosis and HIV infection. 
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